The company describes Solia CSP S as the world’s first pacing lead to combine the support of a style-driven lead platform with the efficiency of a fixed helix. According to Biotrinik, it’s the first pacing lead specifically designed for LBBAP.
Approval enables Biotronik to bring the system to the U.S. market as it seeks to compete against pacing leaders Abbott and Medtronic, which both delivered positive trial outcomes for their LBBAP systems last year.
Biotronik designed its system with an optimized helix, enhanced steerability and simplified handling. It aims to reduce preparation time while improving procedural efficiency and ease of delivery.
The company’s Solia CSP S pacing lead builds on previous technology for LBBAP. The company received expanded FDA approval for its Selectra 3D catheter and Solia S lead for use in LBBAP in 2024.
Dr. Christopher Liu, medical director of cardiac electrophysiology services for the New York-Presbyterian – Weill Cornell Network, said in a news release that Solia CSP S “provides a purpose-built solution long overdue for conduction system pacing.”
Biotronik plans to showcase Solia CSP S and deliver demonstrations, hands-on training and discussions on LBBAP and physiologic pacing at the Heart Rhythm Society Annual Scientific Sessions in Chicago in April.
“With FDA approval, we reinforce our dedication to continued innovation in the critical field of CSP,” said Ryan Walters, President, Biotronik. “Solia CSP S reflects our commitment to advancing physiologic pacing and equipping clinicians with solutions that enhance patient outcomes.”
